Display Settings:

Format

Send to:

Choose Destination
    Mol Med. 2010 Jan-Feb;16(1-2):10-8. Epub 2009 Nov 17.

    Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.

    Source

    Department of Biochemistry and Biophysics, University of Rochester Medical School, Rochester, New York, United States of America.

    Abstract

    The main circulating estrogen hormone 17beta-estradiol (E2) contributes to the initiation and progression of breast cancer. Estrogen receptors (ERs), as transcription factors, mediate the effects of E2. Ablation of the circulating E2 and/or prevention of ER functions constitute approaches for ER-positive breast cancer treatments. These modalities are, however, ineffective in de novo endocrine-resistant breast neoplasms that do not express ERs. The interaction of E2-ERs with specific DNA sequences, estrogen responsive elements (EREs), of genes constitutes one genomic pathway necessary for cellular alterations. We herein tested the prediction that specific regulation of ERE-driven genes by an engineered monomeric and constitutively active transcription factor, monotransregulator, provides a basis for the treatment of ER-negative breast cancer. Using adenovirus infected ER-negative MDA-MB-231 cells derived from a breast adenocarcinoma, we found that the monotransregulator, but not the ERE-binding defective counterpart, repressed cellular proliferation and motility, and induced apoptosis through expression of genes that required ERE interactions. Similarly, the monotransregulator suppressed the growth of ER-negative BT-549 cells derived from a breast-ductal carcinoma. Moreover, the ERE-binding monotransregulator repressed xenograft tumor growth in a nude mice model. Thus, specific regulation of genes bearing EREs could offer a therapeutic approach for de novo endocrine-resistant breast cancers.

    PMID:
    19946606
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2781301
    Free PMC Article

    Images from this publication.See all images (6) Free text

    Figure 2
    Figure 4
    Figure 6
    Figure 1
    Figure 3
    Figure 5

      Supplemental Content

      Icon for ScholarOne, Inc. Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk